LKB1 loss is a frequent homozygous deletion and/or gene mutation found in lung adenocarcinomas. However, few cases of LKB1 loss by either deletion or mutation are seen in Asian patients. Our preliminary data showed that LKB1 loss was associated with p53 mutation in lung tumors from Taiwanese adenocarcinoma patients and p53 transcription is directly regulated by NKX2-1. Therefore, we hypothesized that LKB1 loss could occur due to aberration of p53 regulation mediated by NKX2-1. In the present study, 16 lung adenocarcinoma cell lines were investigated to determine if LKB1 transcription could be deregulated by NKX2-1-mediated p53 aberration. Mechanistic studies indicated that LKB1 was directly upregulated by p53 and that NKX2-1-mediated p53 expression may positively regulate LKB1 expression in p53 wild-type cells. However, in p53-mutated cells, LKB1 transcription was deregulated by NKX2-1 via suppression of SP1 binding onto the LKB1 promoter. Therefore, the action of the NKX2-1/p53 pathway on LKB1 loss differed in p53 wild-type versus p53-mutated cells. As expected, soft-agar growth and invasion capability was significantly reduced by ectopic expression of NKX2-1 in p53 wild-type cells, but it was markedly elevated by silencing NKX2-1 in p53-mutated cells. Similar reciprocal observations were also seen in lung tumors from lung adenocarcinoma patients with either wild-type or mutated p53 tumors. Cox regression analysis showed that patients with low-LKB1 tumors had poorer overall survival (OS) and relapse-free survival (RFS) when compared with patients with high-LKB1 tumors. In p53 wild-type patients, shorter OS and RFS periods were predicted for low-NKX2-1/low-LKB1 tumors than for high-NKX2-1/high-LKB1 tumors. In patients with p53-mutated tumors, poorer OS and RFS were predicted for high-NKX2-1/low-LKB1 tumors than for low-NKX2-1/high-LKB1 tumors. In summary, losses of LKB1 at the transcriptional level by altered activity of the NKX2-1/p53 pathway may promote tumor malignancy and poor patient outcome.
INTRODUCTION
Lung adenocarcinoma has surpassed squamous cell carcinoma to become the predominant subtype of non-small-cell lung cancer. [1] [2] [3] Therefore, most studies regarding lung cancer have focused on the molecular mechanisms of lung adenocarcinoma for establishing a better early diagnosis and clinical treatment for this disease. Large-scale genomic analysis of lung adenocarcinoma has yielded a better understanding of genetic alterations. 4, 5 Loss of the LKB1 gene is found in up to 30% of lung cancers, and Lkb1-deficient lung tumors in mice have a high penetrance of lymph node and distant metastases. 6 Therefore, LKB1 inactivation is a common event that is associated with the progression of lung adenocarcinoma.
The LKB1 gene maps to the chromosomal region 19p13.3, which is a frequent homozygous deletion in Caucasian lung cancer patients (35%), 7 and occurs as a few deletions in African-Americans (6%). 7 In addition, the LKB1 gene product is also frequently dysfunctional due to mutation of the gene in lung adenocarcinoma cell lines and in tumors from Caucasians (20-30%). [7] [8] [9] [10] [11] [12] However, East Asian populations, including Japanese, Korean and Chinese, have a low percentage of LKB1 mutations (3-7%). [13] [14] [15] [16] Our data also indicate a lower frequency of LKB1 mutation (1 of 115, 1.0%) or homozygous deletion (4 of 88, 4.5%) in Taiwanese lung adenocarcinoma patients (Supplementary Table 1 and Supplementary  Figure 1 ). This reveals the possibility that in Asian populations, including Taiwanese, LKB1 loss in lung cancers could be caused by some mechanisms other than gene mutation or homozygous deletion. LKB1 signaling has been implicated in cell cycle arrest and cell death through a mechanism involving p53. 17 For example, LKB1 cooperates with p53 to upregulate p21 transcription. 18, 19 Conversely, mutants catalytically deficient in LKB1 show enhanced expression of cyclin D1 and greater cell proliferation via a p53-independent pathway. 20 An animal model with a homozygous deletion of Lkb1, combined with a Kras mutation, shows a greater formation of frequently metastatic tumors when compared with single-mutant models lacking only p53 or having only Kras mutations. 21 Therefore, Lkb1 appears to act as a critical barrier to the progression of Kras-mutated lung adenocarcinoma. However, p53 À / À mice had been shown to promote earlier onset of gastric hamartomas and hepatic tumors in Lkb1 þ / À p53 À / À mice than in Lkb1 þ / À mice. 22, 23 This could indicate that LKB1 promotes apoptosis via a p53-dependent pathway. 17 Therefore, we expected that a reciprocal regulation might exist between LKB1 and p53, and that this regulation could have a role in lung tumorigenesis. Surprisingly, our preliminary immunohistochemical data showed that low-LKB1 expression was more frequently found in lung adenocarcinoma patients with p53-mutated tumors than with p53 wild-type tumors. This observation prompted us to hypothesize that p53 aberration could cause downregulation of LKB1 and subsequently promote tumor progression. Our preliminary data showed that NKX2-1, a transcription factor of p53, directly activates p53 transcription. In the present study, we have explored the possibility that alteration of the NKX2-1/p53 pathway could deregulate LKB1 transcription and give rise to LKB1 loss.
LKB1 mutations and homozygous deletions have been shown to promote tumor progression in lung adenocarcinoma; 6, 12, [21] [22] [23] however, to our knowledge, the prognostic significance of LKB1 loss on overall survival (OS) and relapse-free survival (RFS) has not yet been reported. In the present study, we provide molecular evidence that lung adenocarcinoma cells expressing low-NKX2-1/ p53 wild-type or high-NKX2-1/p53-mutation show LKB1 loss and a significant promotion of anchorage-independent soft-agar growth and invasive capability. A similar association between NKX2-1 and LKB1 was also observed in vivo in lung adenocarcinoma patients. Patients with low-NKX2-1/p53 wild-type tumors or high-NKX2-1/ p53-mutated tumors showed low-LKB1 expression and had poorer OS and shorter RFS than did patients with high-NKX2-1/p53 wildtype tumors or low-NKX2-1/p53-mutated tumors.
RESULTS
LKB1 loss was correlated with alteration of the NKX2-1/p53 pathway LKB1 has been shown to cooperate with p53 to activate p21 transcription. 18, 19 Our preliminary data showed that p53 transcription can be regulated by NKX2-1. In the present study, we examined whether LKB1 expression could be associated with the p53 mutational status seen in lung tumors. We collected six each of p53 wild-type and p53-mutated lung cancer cell lines to verify this possibility. As shown in Figure 1a , LKB1 expression was not associated with p53 mutation status. LKB1 mRNA and protein expressions were positively correlated with NKX2-1 mRNA and protein expression in p53 wild-type cells, and were negatively associated with NKX2-1 mRNA and protein expressions in p53-mutated H441, TL13 and H1355 cells, but no correlations were observed in p53-null H358, H1299 and p53-mutated H23 cells. Interestingly, LKB1 expression was increased by NKX2-1 knockdown in H358 cells and was decreased by NKX2-1 overexpression in H1299 and H23 cells (Supplementary Figure 2) . This modulation of LKB1 expression by NKX2-1 knockdown or -overexpression in H358, H1299 and H23 cells was consistent with the modulation observed in H441 and TL13 cells.
A series of CL1-0, CL1-1, CL1-3 and CL1-5 lung adenocarcinoma cells with p53 mutation (R248W), which ranged from low to high invasive potential, 24 were enrolled to test the association between LKB1 and NKX2-1 expression (Figure 1b) . LKB1, NKX2-1, p53 and p21 showed gradual and concomitant decreases in this series with increasing invasive potential. The expression of phosphorylatedAMPKa, which was used for detection of the LKB1 protein kinase activity, was significantly higher in the high-LKB1-expressing CL1-0 and CL1-1 cells than in the low-LKB1-expressing CL1-3 and CL1-5 cells, but the total amount of AMPKa was not changed in these cells. These results suggest that LKB1 loss was correlated with aberrant functioning of a NKX2-1/p53 pathway in these cell lines.
We verified whether LKB1 was controlled by NKX2-1 by transfecting two short hairpin RNAs (shRNAs) of LKB1 into the high-LKB1-expressing CL1-0 cells. We also transfected a NKX2-1 cDNA expression vector into the low-LKB1-expressing CL1-5 cells (Figure 1c ). LKB1 expression was reduced by NKX2-1 knockdown in the CL1-0 cells, and LKB1 expression was elevated by NKX2-1 overexpression in the CL1-5 cells in a dose-dependent manner (Figure 1c) . These results clearly indicate that LKB1 may be deregulated by alteration of the NKX2-1/p53 pathway in lung adenocarcinoma cells.
Different impacts of NKX2-1 on LKB1 transcription between p53 wild-type and p53-mutated cells We next investigated whether NKX2-1 could positively regulate LKB1 transcription in p53 wild-type cells. We estimated LKB1 expression in TL10 and CL3 cells in which NKX2-1 was ectopically Figure 1 . Correlation of NKX2-1 with p53 and LKB1 expression in p53 wild-type and p53-mutated lung adenocarcinoma cells. (a) The mRNA and protein expression of NKX2-1, p53 and LKB1were measured by western blotting and real-time RT-PCR in p53 wild-type (TL11, H1650, H1975, TL10, CL3 and A549), p53-mutated (H441, TL13, H1355 and H23) and p53-null (H358 and H1299) lung cancer cells and (b) a series of CL1 cells, which had gradually invasive potential (CL1-54CL1-34CL1-14CL1-0), has been established; and (c) CL1-0 and CL1-5 cells were, respectively, transfected with two kinds of shNKX2-1 (no. 1 and no. 2) and NKX2-1 cDNA plasmid for 48 h. Cell lysates were then harvested to evaluate the protein expression of NKX2-1, p53 and LKB1 by western blotting and the LKB1 mRNA levels by real-time RT-PCR. b-actin served as the protein loading control, and p-AMPKa versus total AMPKa protein expression served as the LKB1 kinase activity. GAPDH was the internal control for real-time RT-PCR.
expressed (in TL10 cells) using a NKX2-1 cDNA plasmid or silenced (in CL3 cells) using two shRNAs (Figure 2a ). LKB1 expression was elevated when NKX2-1 was ectopically expressed in TL10 cells and its expression was reduced when NKX2-1 was silenced in CL3 cells. The change in LKB1 protein and mRNA expression in response to ectopic expression of NKX2-1 or to silencing of NKX2-1 was consistent with levels of phosphorylated-AMPKa expression in the TL10 and CL3 cells. Both cells were further enrolled to test whether NKX2-1 could modulate LKB1 expression in these two p53 wild-type cells with a shp53 transfection. Western blot showed that p53 expression was almost abolished by p53-knockdown, but NKX2-1 expression was not changed by p53-knodown in both cell types when compared with their NC cells. Interestingly, LKB1 protein and its mRNA levels were partially rescued by NKX2-1 knockdown; however, LKB1 protein and its mRNA expression were further reduced by NKX2-1 overexpression in these two p53-knockdown cells (Figure 2b ). These results suggest that NKX2-1-mediated p53 is responsible for LKB1 expression in p53 wild-type lung adenocarcinoma cells. In p53-mutated H441 and TL13 cells, we saw a reversal of this pattern for NKX2-1-dependent expression of LKB1 and phosphorylated-AMPKa (Figure 2c) . Therefore, NKX2-1 had different effects on LKB1 expression in cells that depended on the expression of wild-type versus mutated p53. LKB1 loss at the transcription level: deregulation by alteration of the NKX2-1/p53 pathway We constructed a À 1266 to þ 1 LKB1 promoter (P1), which had two SP1, one FOXO3a, and two p53 putative binding sites, as assessed by a software analysis (Figure 3a, upper panel) . We also used a deletion mutation to construct À 686 to þ 1 (P2), À 302 to þ 1 (P3) and À 1266 to þ 1 (P4) promoters for LKB1 (Figure 3a , upper panel). A luciferase reporter assay indicated that the P3 reporter activity in the p53 wild-type CL3 and TL10 cells was B75% of the P1 reporter activity (Figure 3a , middle panel). This result suggests that binding of p53 to its putative binding sites on the P3 promoter might be responsible for regulation of LKB1 transcription. However, the p53-mutated cells (TL13 and H441) showed an almost complete lack of reporter activity with the P2 and P3 promoter, while the reporter activity with the P4 promoter was B80% of the activity seen with the P1 promoter (Figure 3a , bottom panel). These results indicate that SP1 and FOXO3a may be responsible for LKB1 transcription in p53-mutated TL13 and H441 cells.
We next examined whether NKX2-1 could modulate the P3 and P4 promoters in p53 wild-type and p53-mutated cells. The luciferase reporter assay indicated that the reporter activity with the P3 promoter was markedly decreased by NKX2-1 knockdown in p53 wild-type TL10 and CL3 cells (Figure 3b ). The p53 and LKB1 expressions were decreased by NKX2-1 knockdown in p53 wildtype TL10 and CL3 cells. However, a decrease in p53 and an increase in LKB1 expression were observed in NKX2-1 knockdown H441 and TL13 cells which harbored p53 mutations ( Figure 3b , bottom panel). Consistently, the reporter activity with the P4 promoter was increased by NKX2-1 knockdown in p53-mutated H441 and TL13 cells (Figure 3b ). These results clearly indicate that NKX2-1 has a reciprocal effect on LKB1 transcription in p53 wildtype and p53-mutated lung cancer cells.
We delineated how NKX2-1 exerts this opposite effect on LKB1 transcription between p53 wild-type and p53-mutated cells by performing chromatin immunoprecipitation (ChIP)-qPCR analysis on the P3 and P4 promoters. The putative binding sites of p53 on the P3 promoter and the SP1-binding site on the P4 promoter are shown in Figure 4a We next used site-directed mutagenesis to mutate the p53-and SP1-binding sites on the P3 and P4 promoters (Figure 4b ). The reporter activities of the P3 and P4 promoters were both gradually reduced when the p53-or SP1-binding sites were mutated and SP1 ( À 1256 to À 1248 and À 1063 to À 1055) on the LKB1 promoter were discovered by PROMO analysis (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/ promoinit.cgi?dirDB=TF_8.3). The binding activity of p53 and SP1 on the LKB1 promoter was evaluated by ChIP-qPCR analysis after the p53 wild-type (CL3 and TL10) and p53-mutated (H441 and TL13) cells were transfected with shRNAs to knock down NKX2-1 or p53 or were treated with MTM (50 nM; an SP1 DNA-binding inhibitor) and compared with the non-specific shRNA controls (shNC) (middle panel). The expression of NKX2-1, p53, SP1 and LKB1, in cells transfected with shNKX2-1 or shp53 or treated with MTM, were determined by western blotting using b-actin as the protein loading control (bottom panel). (b) The target sequence of the P3 and P4 promoter were mutated by site-directed mutagenesis to create a mutant series of P3 and P4 promoters. The reporter activity of these mutants was measured by luciferase assays after promoters were transiently transfected into these cells. promoter (P1, À 1266 to þ 1). The P1 promoter was used to construct three promoters by deletion mutation (P2, À 686 to þ 1; P3, À 302 to þ 1; P4, À 1266 to À 687). The reporter activities of P1, P2, P3 and P4 were measured by luciferase reporter assays after transient transfection with these promoters into p53 wild-type (TL10 and CL3) and p53-mutant cells (H441 and TL13), respectively. (b) The P3 promoter was transfected into p53 wild-type CL3 and TL10 cells in which NKX2-1 was knocked down by shNKX2-1 (no. 1). The reporter activity of the P3 promoter was measured by a luciferase reporter activity (upper left panel). P4 promoter was transfected into p53-mutated H441 and TL13 cells in which NKX2-1 was ectopically expressed by a NKX2-1 cDNA plasmid. The reporter activity of the P4 promoter was determined by a luciferase reporter assay (upper right panel). The b-gal served as the internal control for luciferase reporter assay. The NKX2-1, p53, SP1 and LKB1 expressions were determined by western blotting in cells transfected with shNKX2-1 or NKX2-1 cDNA plasmid (bottom panel). b-actin was a protein loading control.
LKB1 loss due to alteration of the NKX2-1/p53 pathway promotes anchorage-independent soft-agar growth and invasion efficacy As mention above, LKB1 loss due to alteration of the NKX2-1/p53 pathway was shown in lung adenocarcinoma cells. We next examined whether LKB1 loss due to NKX2-1-mediated p53 aberration could promote tumor malignancy as indicated by measurements of anchorage-independent soft-agar growth and Boyden chamber assays of lung cancer cell lines. The soft-agar growth and invasion capability were reduced in a dose-dependent manner in NKX2-1-overexpressing TL10 cells and were elevated in NKX2-1 knockdown CL3 cells (Figure 5a ). As expected, the softagar growth and invasion capability were decreased by LKB1 ectopic expression in NKX2-1 knockdown H441 cells. However, both of these capabilities were increased by silenced LKB1 expression in the NKX2-1-overexpressing TL13 cells (Figure 5b) . The ability for soft-agar growth and invasion was restored when NKX2-1 knockdown H441 cells were transfected with LKB1 shRNA (Figure 5b ). The representative decreases or increases in sizes of the colonies formed on soft-agar plates were consistent with the changes in levels of LKB1 due to NKX2-1 knockdown or -overexpression. The LKB1 loss resulting from alteration of the NKX2-1/p53 pathway promoted anchorage-independent soft-agar growth and invasiveness.
Low-LKB1 tumors occurred frequently in patients with advanced stage and nodal metastasis We examined whether low-LKB1 tumors was more commonly observed in late-stage lung cancer patients than in early-stage lung cancer patients. We collected 115 tumors resected from lung adenocarcinoma patients to evaluate LKB1 protein expression by IHC analysis. Low-LKB1 tumors were more frequently observed in patients with late-stage tumors (stage III) than with early-stage tumors (stages I and II) (46% versus 77 and 71%; P ¼ 0.007; Table 1 ). In addition, the LKB1 expression was negatively correlated with nodal metastasis (N). The prevalence of low-LKB1 tumors was significantly higher in patients with advanced nodal metastasis (N2, N3) than with non-nodal or N1 nodal metastasis (N0, N1) (Po0.001; Table 1 ). Real-time RT-PCR analysis showed that LKB1 mRNA expression levels in lung tumors were positively correlated with LKB1 protein expression (Po0.001, Table 1 ). These results were consistent with the observations made with the lung cancer cell models, and suggested that a low-LKB1 expression was associated with tumor aggressiveness in patients with lung adenocarcinomas.
LKB1 is positively correlated with NKX2-1 mRNA expression in p53 wild-type tumors, but p53-mutated tumors show a negative correlation with both LKB1 and NKX2-1 mRNA expression As previously described, LKB1 behaves as a transcriptional target of p53 in lung adenocarcinoma cells. We therefore examined whether LKB1 transcription had any association with p53 mutational status in lung adenocarcinoma patients. As expected, tumors with low expression of LKB1 mRNA were more frequently found in patients with p53-mutated tumors than with p53 wildtype tumors (P ¼ 0.027, Table 2 ). LKB1 mRNA expression was not associated with NKX2-1 mRNA expression in the overall study Table 2 ); however, when this population was divided into p53 wild-type and p53-mutated subgroups, LKB1 expression levels were positively correlated with NKX2-1 mRNA expression in the p53 wild-type subgroup (P ¼ 0.022; Table 2 ), but were negatively correlated with NKX2-1 mRNA expression in the p53-mutated subgroup (P ¼ 0.001). These observations in lung tumors were consistent with the findings from lung cancer cell models, which supported the possibility that a low-LKB1 expression due to alteration of the NKX2-1/p53 pathway may promote tumor aggressiveness in lung adenocarcinoma patients.
LKB1 loss due to alteration of the NKX2-1/p53 pathway was associated with poor OS and RFS in lung adenocarcinoma patients We next examined whether a low-LKB1 expression could be associated with prognosis in lung adenocarcinoma patients. LKB1 expression in lung tumors was evaluated by immunohistochemistry and the representative high and low immunostaining results were shown in Figure 6a . In our study population, all patients (n ¼ 115) were available for RFS analysis with a median follow-up month of 26.4. In the RFS analysis, the condition relapsed in 45 patients (5 local recurrence, 28 distant metastasis and 12 local recurrence/distant metastasis) and 42 patients died from this disease. No patients received adjuvant treatment before surgical therapy. Kaplan-Meier analysis showed that no prognostic value of NKX2-1 mRNA and p53 status on OS and RFS was observed in the overall study population (Figure 6b ). However, OS and RFS were shorter for patients with low-LKB1 tumors than with high-LKB1 tumors (P ¼ 0.002 for OS and RFS, Figure 6b ). Interestingly, OS and RFS were also shorter for patients with low-NKX2-1 mRNA/ low-LKB1 tumors than with high-NKX2-1 mRNA/high-LKB1 tumors (Po0.001 for OS and RFS, Figure 6c ). However, no prognostic significance was seen in patients with high-NKX2-1 mRNA/low-LKB1 tumors when compared with patients with low-NKX2-1 mRNA/high-LKB1 tumors (P ¼ 0.060 for OS, P ¼ 0.086 for RFS; Figure 6d) . A Cox regression model was used to examine whether LKB1, NKX2-1 and p53 could be associated with OS and RFS in lung adenocarcinoma patients. As shown in Table 3 , poorer OS and RFS were seen in patients with low-LKB1 tumors than with high-LKB1 tumors (HR: 1.868, 95% CI: 1.160-3.007, P ¼ 0.010 for OS; HR: 1.791, 95% CI: 1.132-2.834, P ¼ 0.013 for RFS). Median survival was shorter in patients with low-LKB1 tumors than with high-LKB1 tumors (17.1 month versus 43.7 months for OS; 13.1 months versus 39.0 months for RFS). No prognostic value of p53 mutation and NKX2-1 mRNA levels was observed in this study population. The median value of LKB1 mRNA level was used to divide tumors into 'low' and 'high' subgroups. (10) 14 (74) 5 (26) The median value of NKX2-1 and LKB1 mRNA level in this studied population was used to divide into 'low' or 'high' subgroups.
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We explored whether lower expression of LKB1 due to NKX2-1-mediated p53 aberration could be associated with clinical outcome by evaluating the prognostic value of NKX2-1 mRNA and with LKB1 immunostaining for OS and RFS in patients who had p53 wild-type and p53-mutated tumors. In p53 wild-type patients, shorter OS and RFS periods were predicted for patients with low-NKX2-1/low-LKB1 tumors than with high-NKX2-1/high-LKB1 tumors (HR: 3.837, 95% CI: 1.728-8.520, P ¼ 0.001 for OS; HR: 4.020, 95% CI: 1.867-8.654, Po0.001 for RFS; Table 3 ). In p53-mutated patients, shorter OS and RFS periods were predicted for patients with high-NKX2-1/low-LKB1 tumors than with low-NKX2-1/high-LKB1 tumors (HR: 8.007, 95% CI: 1.456-44.036, P ¼ 0.017 for OS; HR: 5.233, 95% CI: 1.043-26.270, P ¼ 0.044 for RFS; Table 3 ). Consistently, shorter median survival was seen in patients with low-NKX2-1/low-LKB1 tumors in p53 wild-type subgroup than in patients with high-NKX2-1/high-LKB1 tumors (12.0 months versus 54.2 months for OS; 10.1 months versus 47.4 months for RFS). In the p53-mutated subgroup, shorter median survival periods were seen in patients with high-NKX2-1/low-LKB1 tumors than in patients with low-NKX2-1/high-LKB1 tumors (14.0 months versus 40.3 months for OS; 13.1 months versus 40.3 months for RFS). These results on the outcomes of lung adenocarcinoma patients strongly supported the findings of the cell models. We therefore suggest that a low-LKB1 expression due to alteration of the NKX2-1/p53 pathway was associated with poor OS and RFS in lung adenocarcinoma patients.
DISCUSSION
LKB1 loss commonly occurs via LKB1 mutations and homozygous deletions in lung adenocarcinoma. [7] [8] [9] [10] [11] [12] In this study, LKB1 protein expression was positively correlated with its mRNA expression both in lung cancer cells and in tumors. Consistent with previous studies, loss of heterozygosity was not associated with LKB1 protein and mRNA expression levels in this study (Supplementary  Table 1) . 8, 21 Representative microsatellite amplifications of marker D19S209 and D19S216 on chromosome 19p13.3 are shown in Supplementary Figure 1 . This observation supports our present assumption that LKB1 expression was predominantly regulated by its transcriptional levels, and not by 19p13.3 allelic imbalance or gene mutations.
In an animal model, the finding that early onset of gastric hamartomas and hepatic adenomas/adenocarcinomas was more common in Lkb1 þ / À p53 À / À compound mutant mice than in mice with single Lkb1 þ / À or p53 À / À mutations suggested that p53 À / À may synergistically enhance tumor progression in Lkb1 þ / À mice. 21 Lkb1 haploinsufficiency can act cooperatively with oncogenic Kras G12D to cause pancreatic ductal adeno- carcinoma in the mouse. 25 Mechanistic studies indicated that this was associated with a decrease in p53/p21-dependent growth arrest. Remarkably, all tumors that had low levels of LKB1 also had low levels of p21 and these tumors did not express mutant p53. 25 Therefore, downregulation of LKB1 may serve as an alternative to p53 mutation as a driver of pancreatic cancer in vivo. These observations in this animal model were consistent with our cell model data, which that showed that LKB1 expression correlated with p53 and p21 expression in a series of CL1 cell lines that showed a range of LKB1 expression (Figure 1b) . Moreover, the presence of alteration of the NKX2-1/p53 pathway and associated with LKB1 loss appeared to promote tumor malignancy and poor patient outcome ( Figure 5 , Table 3 ).
NKX2-1 is frequently amplified in tumors from lung adenocarcinoma patients 4 and is therefore considered to have an oncogenic role in lung adenocarcinoma development. 4, 26 However, Nkx2-1 acts as tumor suppressor in lung adenocarcinoma progression in Kras G12 p53 À / À mice. 27 In addition, NKX2-1 expression may be a marker that predicts poor prognosis in lung adenocarcinoma patients. [28] [29] [30] In the present study, low expression of LKB1 was more frequent in p53-mutated cells and tumors than in p53 wild-type cells and tumors. Mechanistic studies supported the observation in cell and tumors that LKB1 loss at the transcription level is deregulated by the NKX2-1/p53 pathway. In p53 wild-type cells, NKX2-1-mediated p53 expression significantly increased LKB1 expression via increased binding activity of p53 to the LKB1 promoter. Based on this observation, LKB1 appears to be directly regulated by a NKX2-1-mediated p53 pathway, which implicates NKX2-1 as a tumor suppressor that functions via upregulation of LKB1 transcription. In p53-mutated cells, NKX2-1 suppressed LKB1 expression by decreasing the binding of SP1 onto the LKB1 promoter, suggesting that its oncogenic role in p53-mutated cells may depend on suppression of LKB1 expression. This dual role of NKX2-1 in the control of LKB1 transcription may explain, at least in part, why NKX2-1 shows both tumor suppressor and oncogenic properties in lung adenocarcinoma cells.
We further used A427 cells with LKB1 homozygous deletion 21 as a negative control to test whether LKB1 cannot be regulated by the NKX2-1/53 pathway. As expected, LKB1 expression was not seen in A427 cells and its expression level was not changed by NKX2-1, wild-type p53 or mutated p53 (R248W and R158L) transfection (Supplementary Figure 3, right panel) . Interestingly, LKB1 expression levels in p53-null H358 cells were elevated by wild-type p53 or mutated p53 (R248W) transfection, but LKB1 expression levels were not changed by mutated p53 (R158L) transfection, and expectedly, LKB1 expression was reduced by NKX2-1 transfection in p53 aberrant H358 cells (Supplementary Figure 3, left panel) . These observations were consistent with our previous report and indicated that p53 mutated at R248W possessed a partial p53 transcriptional activity when compared with that of p53 gene with other hotspot mutations. 31 These results further supported the possibility that LKB1 expression was modulated by the NKX2-1/p53 pathway in lung adenocarcinoma cells.
We next explored the individual and combined effects of NKX2-1, p53 and SP1, on LKB1 transcription in the same p53-null H1299 cells. These cells were transfected with NKX2-1, wild-type p53, mutated p53 (R158L) and SP1 expression vectors, or treated with MTM, as well as combinations of treatments. ChIP-qPCR analysis showed that SP1 clearly bound to the LKB1 promoter in p53-null H1299 cells, and this binding of SP1 to the LKB1 promoter was significantly decreased by NKX2-1, wild-type p53 and MTM, but was not changed by mutated p53 (Supplementary Figure 4 , left panel). The suppression of binding of SP1 onto the LKB1 promoter by NKX2-1 or wild-type p53 could be rescued by SP1, but the restoration was completely abolished by treatment with MTM (Supplementary Figure 4, middle panel) . On the other hand, Figure 4 , right panel). Real-time RT-PCR and luciferase reporter assays showed that LKB1 mRNA expression and the reporter activity of the LKB1 promoter ( À 1266 to þ 1) were consistent with the binding of wild-type p53 or SP1 onto the LKB1 promoter (Supplementary Figure 4, bottom panel) . These results suggest that the LKB1 transcription is more pronouncedly regulated by wild-type p53 than by SP1 in p53-null H1299 cells that had low-NKX2-1 expression. The proposed mechanistic action of the NKX2-1/p53 pathway on LKB1 transcription is shown in Supplementary Figure 5 . In summary, we provide a novel evidence to demonstrate that LKB1 loss is predominantly due to alteration of the NKX2-1/p53 pathway and that deregulation occurs at the transcriptional level, rather than through gene mutations and/or loss of heterozygosity. The findings from cell models were consistent with findings from tumors from lung adenocarcinoma patients, indicating that LKB1 loss promotes in vivo tumor malignancy, poor patient survival and cancer relapse.
MATERIALS AND METHODS Patients
Lung tumor specimens were collected from 115 unselected lung cancer patients diagnosed with lung adenocarcinoma at the Department of Thoracic Surgery, Taichung Veteran's General Hospital (TVGH, Taichung, Taiwan) between 1994 and 2004. Written informed consent for a biology study was obtained from patients before sample collection. Tumor stages were determined according to the WHO classification. Tissues were stored at À 80 1C, immediately after resection.
Cell culture and reagents A427, A549 and H1299 cells were maintained in DMEM; CL1-0, CL1-1, CL1-3, CL1-5, CL3, H1355, H1650, H1975, H23, H358 and H441 cells were maintained in RPMI-1640. The CL1-0, CL1-1, CL1-3, CL1-5 and CL3 cells were kindly supplied by Dr PC Yang (Department of Internal Medicine, National Taiwan University College of Medicine). The A427, A549, H1299, H1355, H1650, H1975, H23, H358 and H441 cells were obtained from ATCC (Manassas, VA, USA). The TL10, TL11 and TL13 cells were primarily established from pleural effusions of Taiwanese lung cancer patients from Chung Shan Medical University Hospital, and these cells were further identified to be adenocarcinoma cells using the procedures and methods as described previously. 32, 33 The TL10 cells were cultured from a pathologically diagnosed lung adenocarcinoma of an 82-year-old female nonsmoker with T4N3M1. The TL11 cells were cultured from a pathologically diagnosed lung adenocarcinoma of a 62-year-old female nonsmoker with T4N3M1. TL10, TL11 and TL13 cells were confirmed to be lung adenocarcinoma cells by specific antibodies (TTF-1, CEA, DAPAS and mucin), which have been described in our previous reports. 32, 33 The medium contained 10% FBS supplemented with penicillin (100 U/ml) and streptomycin (100 mg/ml). Cells were grown at 37 1C in a humidified incubator at 5% CO 2 . The information of gene mutations including KRAS, EGFR, p53 and LKB1 was shown in Supplementary Table 3. MTM was purchased from Sigma (St Louis, MO, USA).
Immunohistochemistry and scoring
Immunohistochemistry (IHC) was used to detect LKB1 protein expression. The LKB1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The immunohistochemical procedures were conducted as previously described. 33 Negative controls were obtained by performing all of the IHC steps, but leaving out the primary antibody. The immunohistochemical staining scores were defined as described previously 33 and the intensities of signals were evaluated independently by three observers. Immunostaining scores were defined as the cell staining intensity (0 ¼ nil; 1 ¼ weak; 2 ¼ moderate; and 3 ¼ strong) multiplied by the percentage of labeled cells (0-100%), leading to scores from 0 to 300. A score higher than 100 was defined as 'high' immunostaining, while a score equal to or lower than 100 was categorized as 'low'.
RNA isolation and real-time quantitative RT-PCR analysis
The methods and procedures for total RNA extraction from tissues and cells were described previously. 34 Primers used for real-time RT-PCR analysis are listed in Supplementary Table 2 . The NKX2-1 and LKB1 mRNA levels in lung tumors that were higher than the median value were defined as 'high', while levels lower than the median value were defined as 'low'.
Western blotting assay and antibodies
The methods and procedures were described previously.
34 NKX2-1 (8G7G3/1), LKB1 (Ley37G/D6), p-AMPKa (E0207), AMPKa (H-300), p21 (F-5) and SP1 (H-225) antibodies were obtained from Santa Cruz Biotechnology. p53 (BP53-12) and b-actin (AC-15) antibodies were obtained from Sigma.
Plasmid construction and transfection reaction
The wild-type and mutant p53 plasmids were kindly provided by Dr JL Ko from the Institute of Medicine at Chung Shan Medical University. The LKB1 and SP1 overexpression plasmids were purchased from Addgene (Addgene Technologies, Cambridge, MA, USA). The NKX2-1 cDNA was cloned into pcDNA 3.1 A( À ) (Invitrogen, San Diego, CA, USA) by PCR amplification with newly created XhoI and KpnI sites attached to the human NKX2-1 5 0 -ends of forward and reverse primers, and TL4 cDNA as a template, respectively. The shp53 (TRCN0000003755), shNKX2-1 (TRCN0000020451, TRCN0000022196), shLKB1 (TRCN0000000411) plasmids and pLKO.1 vector were purchased from National RNAi Core Facility at Academic Sinica, Taiwan. The different concentrations of expression plasmids, as indicated, were transiently transfected into lung cancer cells (1 Â 10 6 ) using the Turbofect reagent (Formentas, USA). After 48 h, cells were harvested and whole-cell extracts were assayed in the subsequent experiments.
Site-directed mutagenesis
The methods and procedures for the site-directed mutagenesis assay were described previously. 35 Site-directed mutagenesis was performed to generate the mutant p53 and SP1-binding sites of LKB1 promoter constructs using the complementary oligos as follows: SP1 ( À 1256 to À 1248) forward: 
Luciferase reporter assay
For the luciferase reporter assay, appropriate numbers of cells were transfected with sufficient reporter plasmid, LKB1-Luc, or its derivatives, p53-Luc and either the control vector or the shNKX2-1 and NKX2-1 expression plasmid. For normalization of transfection efficiency, b-galactosidase (b-gal) was also cotransfected. Transfected cells were harvested at 48 h post-transfection, and a luciferase assay was performed according to the manufacturer's instructions. The luciferase activity was measured with an AutoLumat LB953 luminometer ( Berthold technologies, Bad Wildbad, Germany) and normalized with the cotransfected b-gal activity.
Quantitative ChIP assay (ChIP-qPCR)
ChIP analysis was performed as described in a previous report. 34 ChIP-qPCR analysis was performed using an ABI-7500 with SYBR Green real-time PCR MasterMix (Fermentas, Hanover, MD, USA) following the detailed procedures described previously. 36, 37 The primer sequences for p53-binding sites were the forward primers: 5 0 -CTGCACCGGGCTTGGA-3 0 and the reverse primer, 5 0 -GCCGCCAGCCCTGAGT-3 0 . The primer sequences for SP1-binding sites were the forward primers: 5 0 -TCAGCGGCGGCGGGGCGGG CA-3 0 and the reverse primer, 5 0 -CAGCAAGTGCCGCCACCCGC-3 0 . All signals from immunoprecipitated DNA samples were normalized to the input of cell total DNA. LKB1 loss by NKX2-1/p53 pathway promotes tumor malignancy L-H Tsai et al
